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Traumatic brain injury (TBI) is a major cause of death
and disability among young adults. Recent data show that
TBI affects about 1.7 million people annually in the United
States (Faul and Coronado, 2015). After TBI, the primary
injury produces almost irreparable brain damage. However,
recent experimental studies have shown evidence for
dynamic brain repair following TBI because endogenous
progenitor cells may play regenerative roles in response to
injuries (McGinn and Povlishock, 2015). In surviving
patients, what plays a critical role in the clinical prognosis is
the subsequent secondary injury; without effective treat-
ment, cascades that include glutamatergic excitotoxicity and
calcium overload will promote additional brain damage.
Recently, a growing interest in milder forms of TBI
has blossomed. These usually involve multiple low-impact
injuries, and these injuries are often reported in association
with domestic violence, contact sports, or military activ-
ities (Galgano et al., 2016; Krawczyk et al., 2013; Landre
et al., 2006). Repetitive mild TBI (mTBI) has been associ-
ated with deficits in several functional areas, including
speed of information processing, memory and attention,
and executive functions (McKee et al., 2013), including
verbal learning and delayed recall (McKee et al., 2013,
2015. Accordingly, mTBI can be considered a distinct
condition with respect to the acute sequelae of concussion
or TBI (Gavett et al., 2011). Recent pathological studies
have shown the occurrence of morphological changes in
the brain following repetitive low-impact traumatic injury
events. This includes the progressive development of
chronic traumatic encephalopathy (CTE), which is often
associated with the deposition of tau protein in the brain
parenchyma (Ojo et al., 2016).
Given the unique characteristics of mTBI, the
mechanisms and the clinical scenario underlying such a
form of TBI are an intense area of study. What has
become clear, however, is that the outcome for TBI
patients reflects the direct cellular damage caused by the
primary impact and the cascade of secondary cellular and
molecular responses that are activated following the initial
injury. Understanding these processes underlying mTBI is
of crucial importance, and experimental models would be
helpful. Modeling mTBI, however, has been challenging.
In most of the cases, the mild versions of the common
experimental models of TBI have been based on less
severe degrees of injury. Accordingly, the results do not
represent certainly the clinical scenario of human mTBI.
In this issue of the Journal of Neuroscience Research,
Zander and collaborators report the first indoor primary
blast model, which uses military explosives in a controlled
environment. They examined the effects of primary rat
neurons and mixed cultures exposed to single and
repeated blasts in order to simulate explosive blast-
induced mTBI. Their findings clearly show that blast
exposure disrupts the integrity of the plasma membrane,
leading to the upset of ion homeostasis, formation of reac-
tive oxygen species, and glutamate release. This mTBI
model will be useful in studying the underlying patho-
physiology of brain injury and in investigating the vulner-
ability of the injured brain to second insults. Although the
study tries to reproduce a real scenario, it must be consid-
ered that this is an in vitro study and the results obtained
are related to a particular type of explosive in an indoor
platform. Accordingly, the effects experienced outside or
with a different explosive may be different. Furthermore,
injuries experienced by animals or humans will likely dif-
fer from the in vitro effects obtained with this model.
Therefore, additional studies are necessary to validate the
results of this study, and this would only be possible by in
vivo studies and a direct comparison with data collected
from injured persons or cadaveric analyses.
What we do know is that mTBI sequelae clearly
affect the performance in work and leisure activities as
long as the brain is injured. Accordingly, given the high
incidence of this condition, the economic burden of such
pathology is considerable. Military personnel and contact
sports athletes who experienced mTBI are at significantly
increased risk for adverse occupational outcomes. Transla-
tional research and clinical trials focusing on treatments
blossoming from experimental research can lead to the
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development of effective actions for counteracting the
sequelae of mTBI. However, many researchers have long
explored agents with possible beneficial effects following
TBI. Although several compounds have been demon-
strated to be effective in preclinical models, only some of
these have entered clinical development, and some of
those that survived early safety trials have been studied in
controlled efficacy trials. Despite these efforts, all phase III
trials have so far failed to demonstrate efficacy of these
agents (Grasso et al., 2016). The pathophysiological heter-
ogeneity of TBI-affected patients and the absence of satis-
factory pharmacokinetic investigations necessary to assess
optimal doses and timing for administration might have
led to the clinical trial failures. Experimental models of
TBI are designed to produce a relatively homogeneous
type of injury, so they may not be able to reproduce fully
all the aspects that are observed in human TBI. This may
in part explain why drugs that showed promise in preclin-
ical studies failed in clinical translation. However, in vitro
and in vivo models have been crucial in exploring both
cellular and molecular mechanisms of human TBI because
of the limitations of the clinical setting as well as in devel-
oping and characterizing novel therapeutic strategies. To
achieve new therapeutic solutions, appropriate experi-
mental paradigms should be designed.
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